Targeting a gene linked to cardiovascular disease shows therapeutic promise.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
Current Atherosclerosis Reports Open Access 28 July 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rothgangl, T. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00933-4 (2021).
Musunuru, K. et al. Nature 593, 429–434 (2021).
Zhang, D. W. et al. J. Biol. Chem. 282, 18602–18612 (2007).
Abifadel, M. et al. Nat. Genet. 34, 154–156 (2003).
Cohen, J. et al. Nat. Genet. 37, 161–165 (2005).
First in vivo human genome editing trial. Nat. Biotechnol. 36, 5 (2018).
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Nat. Biotechnol. 38, 824–844 (2020).
Jin, S. et al. Science 364, 292–295 (2019).
Zuo, E. et al. Science 364, 289–292 (2019).
Chadwick, A. C., Wang, X. & Musunuru, K. Arterioscler. Thromb. Vasc. Biol. 37, 1741–1747 (2017).
Gaudelli, N. M. et al. Nat. Biotechnol. 38, 892–900 (2020).
Hanlon, K. S. et al. Nat. Commun. 10, 4439 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
van Kampen, S.J., van Rooij, E. CRISPR base editing lowers cholesterol in monkeys. Nat Biotechnol 39, 920–921 (2021). https://doi.org/10.1038/s41587-021-00975-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-00975-8
This article is cited by
-
PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
Current Atherosclerosis Reports (2022)